このエビデンス概要は医学的助言ではありません。研究と執筆のための、出典付き文献検索ドラフトです。引用または応用する前に、必ず原論文を確認してください。
研究上の問い
メトホルミンは心血管リスクを低下させるのか？
短い回答
返された文献は、心血管エンドポイント、比較治療、糖尿病の有無、研究デザインを確認して読む必要があります。
検索条件と結果
- 検索した主張: メトホルミンは2型糖尿病患者の心血管リスクを低下させる可能性がある。
- 検索意図: メトホルミンと心血管リスクに関する出典付き生物医学論文を探す。
- 結果セット: この主張について LitSource が返した、出典付きの主要な生物医学論文です。
- 最終更新日: 2026-05-04
見つかった主な論文
| 論文 | 年 | ジャーナル | 出典 | エビデンススニペット |
|---|---|---|---|---|
| Antihyperglycemic Effects of Annona cherimola Miller and the Flavonoid Rutin in Combination with Oral Antidiabetic Drugs on Streptozocin-Induced Diabetic Mice. | 2023 | Pharmaceuticals (Basel, Switzerland) | PMID 36678609 | Several studies have reported the effects of metformin on atherosclerotic vascular disease in people with type 2 diabetes; our results agree with the previous results presented for metformin, and in combination with EEA… |
| Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study. | 2024 | Diabetologia | PMID 39271516 | The recent international study 'REducing with Metformin Vascular Adverse Lesions' (REMOVAL) suggests a reduction in cardiovascular risk as a result of metformin use in people with long-standing type 1 diabetes. |
| Current and future therapies for type 1 diabetes. | 2021 | Diabetologia | PMID 33595677 | In the large REducing With MetfOrmin Vascular Adverse Lesions (REMOVAL) trial, however, metformin did not reduce the long-term insulin needs or improve glycaemic control in people with long-standing type 1 diabetes and… |
| Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. | 2019 | Endocrinology, diabetes & metabolism | PMID 30815577 | Taking all of this together raises the possibility that the combination of metformin, pioglitazone and a SGLT-2 inhibitor might be additive, with regard to reducing, cardiovascular risk in people with diabetes at high c… |
| The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | 2021 | Diabetologia | PMID 34590174 | Metformin has been evaluated in numerous small trials in people with type 1 diabetes with hopes that its insulin-sensitising properties would improve glycaemic management and/or reduce cardiovascular risk. |
| Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial. | 2024 | Journal of clinical medicine | PMID 39598003 | Conclusions: The empagliflozin/metformin combination improved glycemic control, reduced weight and insulin requirements, and produced several additional beneficial metabolic effects in overweight people with type 1 diab… |
| Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide. | 2025 | Diabetes therapy : research, treatment and education of diabetes and related disorders | PMID 40377834 | Diabetes treatment guidelines advocate consideration of GLP-1 RAs as second-line therapy for people with T2D uncontrolled on metformin, and as first-line therapy in patients with T2D and atherosclerotic cardiovascular d… |
| Mechanisms of action of metformin with special reference to cardiovascular protection. | 2019 | Diabetes/metabolism research and reviews | PMID 31021474 | One of these, the REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL) study, demonstrated a minor and transient reduction for metformin vs placebo of one measure of carotid atherosclerosis in p… |
エビデンスが支持しているように見える点
上記の論文は、この主張に対する LitSource の出典付き検索で返された候補文献です。引用する前に、ハイライトされたスニペットを確認し、原論文を開いて文脈を確認してください。
まだ不確かな点
このドラフトは臨床的確実性を順位付けせず、システマティックレビューの方法を置き換えず、この主張を医療判断に使うべきかを決めるものでもありません。引用前に研究デザイン、対象集団、介入内容、効果量、新しさを確認してください。
LitSource でこの検索を試す
この主張を LitSource に貼り付けると、検索を再実行し、更新されたエビデンススニペットを確認し、引用をエクスポートできます。